Alexion Ends Rare Kidney Disease Program Following Poor Data

Alexion Ends Rare Kidney Disease Program Following Poor Data

Source: 
BioSpace
snippet: 

In October 2019, Alexion Pharmaceuticals snapped up Achillon Pharmaceuticals and its oral small molecule Factor D inhibitor program for a rare kidney disease for $930 million in cash. This week, the company shuttered the program following disappointing clinical data.